Remove Documentation Remove HIPAA Remove Labelling
article thumbnail

NHC Comments on Medicare Drug Price Negotiation Program: Draft Guidance, Implementation of Sections 1191 – 1198 of the Social Security Act for Initial Price Applicability Year 2027 and Manufacturer Effectuation of the Maximum Fair Price (MFP) in 2026 and 2027

Putting Patients First Blog

Enhance Dialogue-Based Engagement Clarify Required Disclosures Allow HIPAA Waivers if Feasible Clarify Speaker Selection Process Allow for Data Submissions After Sessions Increase Engagement. Off-label usage often emerges from real- world clinical practice and patient experiences, which might not be reflected in the guidelines.

article thumbnail

Navigating Executive Orders and DOJ Memos That Threaten Criminal Prosecution

FDA Law Blog: Biosimilars

The gray box at the top of the document at this link shows the change in position. Were not trying to bury the lead here, but the battle of labeling these surgical and drug treatments is a political one. Specifically, these are procedures and drugs used in providing what HHS had, until recently, referred to as gender-affirming care.